GeneralMedium•9 November 2026•
1 min read
FDA Mandates Eye Condition Warnings for Ozempic and Mounjaro
Key Facts
1The US FDA ordered new warnings for Ozempic and Mounjaro regarding the risk of non-arteritic anterior ischemic optic neuropathy (NAION).
The US FDA ordered new warnings for Ozempic and Mounjaro labels regarding the risk of non-arteritic anterior ischemic optic neuropathy (NAION). UNILAD reported that the regulatory action follows reports and lawsuits alleging that weight-loss and diabetes drugs, including Wegovy, caused blindness in some patients.
Eli Lilly closed at $1394.66 on November 9, 2026, while Novo Nordisk closed at $40.31 on November 6, 2026. The manufacturers face increasing legal pressure as the new warnings aim to inform patients and healthcare providers of potential risks associated with the GLP-1 class of medications used for type 2 diabetes and long-term weight management.